ReviewActa physiologica (Oxford, England)2026
Renin-Angiotensin Signaling and Vascular Function: Insights into Health and Disease.
Review in Acta physiologica (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The renin-angiotensin system (RAS) is an essential regulator of vascular structure and function, and dysregulation of angiotensin II (Ang II) signaling plays a critical role in the development of hypertension and associated vascular complications. Ang II exerts its vascular actions primarily through the angiotensin II type 1 receptor (AT1R), activating canonical and non-canonical signaling pathways that extend beyond classical G-protein-dependent signaling mechanisms. Here, we review the literature on tissue-specific RAS, Ang II-dependent and Ang II-independent signaling mechanisms of vascular Ang II receptors, and their contribution to vasoconstriction, endothelial dysfunction, vascular remodeling, and arterial stiffness in hypertension. We highlight the roles of mechanosensitive AT1R signaling, dysregulation of vascular ion channels, enhanced reactive oxygen species production, immune and inflammatory signaling, and mineralocorticoid receptor activation as key drivers of hypertensive vascular pathology. In addition, we discuss tissue-specific expression of RAS components and separation between RAS pathways underlying blood pressure elevation and vascular remodeling in hypertension. Collectively, emerging research on vascular Ang II receptor signaling reveals novel regulatory mechanisms and therapeutic opportunities beyond conventional RAS inhibition. Targeting downstream pathways that mediate oxidative stress, mechanotransduction, ion channel activity, and profibrotic signaling may offer improved strategies to prevent or reverse Ang II receptor-dependent vascular dysfunction in hypertension.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.